NextPoint Therapeutics vs Florence Healthcare
Side-by-side comparison of AI visibility scores, market position, and capabilities
NextPoint Therapeutics is a clinical-stage immuno-oncology company targeting the HHLA2 checkpoint with two Phase 1 candidates (NPX267, NPX887); raised $122.5M total including $42.5M Series B extension co-led by Catalio in 2024.
About
NextPoint Therapeutics is a clinical-stage biotechnology company developing precision immuno-oncology therapeutics that target the HHLA2 (B7-H7) immune checkpoint pathway. HHLA2 is a novel checkpoint ligand that suppresses anti-tumor T cell and NK cell activity in many solid tumors independently of PD-L1, providing a rationale for combination with existing checkpoint inhibitors or as a monotherapy in PD-L1-resistant tumors.
Florence Healthcare is the leading clinical trial site enablement platform, connecting 12,000+ research sites in 45 countries; $116M raised from Insight Partners; processes 6.5M+ research workflows monthly via remote digital document management.
About
Florence Healthcare is the dominant software platform for clinical trial site enablement, providing digital tools that connect trial sites, sponsors, and contract research organizations (CROs) to streamline regulatory documentation, remote monitoring, and operational workflows. Founded in Atlanta and backed by Insight Partners, Florence has built the industry's largest connected network of clinical trial sites — over 12,000 sites across 45 countries — making it the infrastructure backbone for decentralized and hybrid clinical research.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.